Faruqi & Faruqi Investigates Aquestive Therapeutics
Analysis based on 50 articles · First reported Jan 29, 2026 · Last updated Mar 13, 2026
The market is negatively impacted for Aquestive Therapeutics as its stock plunged 40% due to the United States===Food and Drug Administration's findings. This event also signals potential legal action, creating uncertainty for investors in Aquestive Therapeutics.
Faruqi & Faruqi, LLP, a national securities law firm, is investigating Aquestive Therapeutics after its stock plunged approximately 40%. This decline followed the United States===Food and Drug Administration's identification of deficiencies in Aquestive Therapeutics' New Drug Application for Anaphylm, an experimental sublingual film for severe allergic reactions. The FDA's findings prevent discussions of labeling and post-marketing requirements, raising concerns about the application's approvability. James Wilson, a partner at Faruqi & Faruqi, is encouraging investors who suffered significant losses to contact him to discuss their legal rights.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard